logo

For the Inventor, By the Inventor

Smyrna, DE, United States of America

James Peter Beck

This inventor holds 13 USPTO granted patents. Top assignees: Dupont Pharmaceuticals Company, Dupont Pharmaceuticals, Inc., Bristol-Myers Squibb Pharma Company. Active years: 2000-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James Peter Beck. Retrieved from https://idiyas.com/inventor/james-peter-beck-m3q3u1hb

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13

% Patents Active = 100.0

Average Co-Inventor Count = 3.3

ph-index = 9

Forward Citations = 256(Granted Patents)


Location History:

  • Newark, DE (US) (2000 - 2001)
  • Smyrna, DE (US) (2000 - 2003)

Company Filing History:

goldMedal6 out of 106 
 
Dupont Pharmaceuticals Company
 patents
silverMedal4 out of 15 
 
Dupont Pharmaceuticals, Inc.
 patents
bronzeMedal3 out of 234 
 
Bristol-Myers Squibb Pharma Company
 patents

Years Active: 2000-2003

Loading Chart...
13 patents (USPTO):Explore Patents
1. 6642230 - Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders (2003-11-04),
2. 6448261 - Arylamino fused pyridines (2002-09-10),
3. 6362180 - Imidazopyridines for the treatment of neurological disorders (2002-03-26),
4. 6258809 - 6-aryloxy and arylthiopurines (2001-07-10),
5. 6245769 - Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders (2001-06-12),
6. 6174912 - Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists (2001-01-16),
7. 6143743 - Imidazopyrimidines and imidazopyridines for the treatment of (2000-11-07),
8. 6124463 - Benzimidazoles as corticotropin release factor antagonists (2000-09-26),
9. 6124300 - Aryloxy- and arylthio- fused pyridines and pyrimidines and derivatives (2000-09-26),
10. 6107301 - 1N-alkyl-N-arylpyrimidinamines and derivatives thereof (2000-08-22),
11. 6107300 - Arylamino fused pyrimidines (2000-08-22),
12. 6107294 - Thiazolo[4,5-d]pyrimidines and pyridines as corticotropin releasing (2000-08-22),
13. 6103737 - Aryl- and arylamino- substituted heterocycles as corticotropin releasing (2000-08-15),

Title: The Innovative Contributions of James Peter Beck

Introduction

James Peter Beck is a notable inventor based in Smyrna, Delaware. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of neurological disorders. With a total of 13 patents to his name, Beck's work has had a profound impact on medical research and development.

Latest Patents

Among his latest patents are "Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders" and "Arylamino fused pyridines." These innovations showcase his dedication to advancing therapeutic options for patients suffering from complex neurological conditions.

Career Highlights

Beck has had a distinguished career, working with prominent organizations such as DuPont Pharmaceuticals Company and DuPont Pharmaceuticals, Inc. His experience in these companies has allowed him to develop groundbreaking solutions that address critical health issues.

Collaborations

Throughout his career, Beck has collaborated with esteemed colleagues, including Rajagopal Bakthavatchalam and Paul Joseph Gilligan. These partnerships have fostered an environment of innovation and creativity, leading to the development of impactful pharmaceutical solutions.

Conclusion

James Peter Beck's contributions to the field of pharmaceuticals are noteworthy and continue to influence the industry. His innovative patents and collaborative efforts reflect his commitment to improving healthcare through scientific advancement.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…